Cellectar Biosciences, Inc.
CLRB
Positions held
Your positionsCLRB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $13.23M | Enterprise value | -$19.23M | Trailing P/E | — | Forward P/E | -0.73 |
| PEG | — | Price / book | 0.39 | Beta | 0.58 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -119.6% | ROA | -58.4% | Debt / equity | 0.05 |
| Current ratio | 6.66 | Free cash flow | -$12.52M | Analyst recommendation | none | Mean target | $11.50 |
| 52w high | $5.07 | 52w low | $1.34 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$6.9M | -$5.7M | -$5.3M | -$4.4M | -$5.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$7.2M | -$5.8M | -$5.7M | -$4.9M | -$6.0M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$21.8M | -$44.6M | -$42.8M | -$31.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.0M | -$51.8M | -$39.0M | -$28.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-20 · Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
2026-08-17 · Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...
2026-08-14 · Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary
2026-08-13 · Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-07-15 · Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
2026-07-11 · Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk
Price (daily)
Full chart · RSI · MACD · patterns